Evidence map›Paper›PMID 28052995›Full record

ArticleInfection and immunity2017

RAGE-Mediated Suppression of Interleukin-10 Results in Enhanced Mortality in a Murine Model of Acinetobacter baumannii Sepsis.

Michael J Noto, Kyle W Becker, Kelli L Boyd, Ann Marie Schmidt, Eric P Skaar

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Insights intoFrontiers in immunology · 2022
    Review
  5. Polymyxin B, Cefoperazone Sodium-Sulbactam Sodium, and Tigecycline against Multidrug-ResistantEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
  6. Article
  7. IL-10 Protects Mice From the Lung Infection ofFrontiers in immunology · 2020
    Article
  8. Host Innate Immune Responses toFrontiers in cellular and infection microbiology · 2020
    Review
  9. Article
  10. Confronting Tigecycline-ResistantFrontiers in microbiology · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Arteriosclerosis, thrombosis, and vascular biology · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Michael J NotoDepartment of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kyle W BeckerDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kelli L BoydDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Ann Marie SchmidtNew York University Langone Medical Center, New York, New York, USA.
Eric P SkaarDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA eric.skaar@vanderbilt.edu.
Vanderbilt University Medical Center · USNYU Langone Health · US

Funding

Host-mediated zinc sequestration during Acinetobacter baumannii infectionR01AI101171 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WALTER J. CHAZIN, DAVID P. GIEDROC · 2013 to 2026
$8.2M
MOLECULAR BIOPHYSICS TRAINING PROGRAM AT VANDERBILTT32GM008320 · NIGMS · VANDERBILT UNIVERSITY · PI CHAZIN, WALTER J. · 1989 to 2023
$7.9M
Clinical and Translational Training Program in Pulmonary MedicineT32HL087738 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Lorraine B Ware · 2007 to 2026
$7.0M
NHLBI NIH HHS T32 HL087738NIAID NIH HHS R01 AI101171NIGMS NIH HHS T32 GM008320
6 · The paper itself

Abstract

The receptor for advanced glycation end products (RAGE) is a pattern recognition receptor capable of recognizing multiple pathogen-associated and danger-associated molecular patterns that contributes to the initiation and potentiation of inflammation in many disease processes. During infection, RAGE functions to either exacerbate disease severity or enhance pathogen clearance depending on the pathogen studied.

Indexed as

SepsisAcinetobacter baumanniiAcinetobacter InfectionsAnimalsDisease Models, AnimalFemaleImmunity, InnateInterleukin-10Kaplan-Meier EstimateLeukocyte CountMiceMice, KnockoutReceptor for Advanced Glycation End ProductsSeverity of Illness IndexSignal TransductionInterleukin-10Receptor for Advanced Glycation End ProductsAcinetobacter baumanniiIL-10innate immunitypneumoniaRAGEreceptor for advanced glycation end productssepsis

Identifiers

PMID28052995
PMCPMC5328494
OpenAlexW2568886428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.